Palatin Announces Intent To Effect 1-For-25 Reverse Stock Split, Effective Aug. 31

Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022 CRANBURY, N.J., Aug. 19, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing

Common Stock Will Begin Trading on a Split-Adjusted Basis on August 31, 2022

CRANBURY, N.J., Aug. 19, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it intends to effect a 1-for-25 reverse split of its issued and outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split will become effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the “Effective Date”), and the Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on August 31, 2022.

Total
0
Shares
Related Posts
Read More

CBD of Denver Reports YoY Increase In 2023 Gross Profit, Reduces Loss As It Continues To Expand Internationally

CBD of Denver, Inc. has filed its financial results for the year ended Dec. 31, 2023.The Colorado-based cannabis company said total current assets increased to $117,218 in 2023, up from $28,043 in 2022. Gross profit for the year totaled $595,417, representing a significant recovery from a gross loss of $284,734 in the prior year, due to a 27% increase in sales and a reduction in cost of goods sold. Net income before provision for income tax showed improvement with a loss of $377,729 in 2023, compared to a loss of $3,257,710 in 2022. CBD of Denver attributed it to the company's efforts to enhance operational efficiency and improve cost management.

CBDD